Johnson & Johnson re-brands to unite its MedTech and pharma segments 

Johnson & Johnson re-brands to unite its MedTech and pharma segments 

Johnson & Johnson, with its focus on healthcare innovation and tackling the toughest health challenges, is updating its brand and uniting both its MedTech and pharmaceutical segments under the Johnson & Johnson brand name to demonstrate its collective power in healthcare. 

The announcement marks the next era for Johnson & Johnson, which is leveraging its expertise in innovative medicine and medical technology to prevent, treat and cure complex diseases and introduce solutions that are smarter, less invasive and more personalised. 

Moving forward, the company’s two segments will be more connected to the Johnson & Johnson brand. Over time, Janssen, the Company’s pharmaceutical segment, will be named Johnson & Johnson Innovative Medicine, and the medical technology segment will continue to be named Johnson & Johnson MedTech.  

“Our exclusive focus on Innovative Medicine and MedTech solutions enables us to innovate across the full spectrum of healthcare in ways no other company can,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “Uniting our diverse businesses under an updated Johnson & Johnson brand reflects our unique ability to reimagine healthcare through transformative innovation while staying true to Our Credo values and the level of care that patients and doctors expect of us.” 

Click below to share this article